Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial

Kreijtz Joost H. C. M.; Goeijenbier Marco; Moesker Fleur M.; van den Dries Lennert; Goeijenbier Simone; De Gruyter Heidi L. M.; Lehmann Michael H.; de Mutsert Gerrie; van de Vijver David A. M. C.; Volz Asisa; Fouchier Ron A. M.; van Gorp Eric C. M.; Rimmelzwaan Guus F.; Sutter Gerd; Osterhaus Albert D. M. E.

首页> 外文期刊>The Lancet infectious diseases >Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial

【24h】

Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial

机译：改良的痘苗病毒-基于安卡拉的甲型H5N1流感疫苗的安全性和免疫原性：一项随机，双盲1 / 2a期临床试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background Modified vaccinia virus Ankara (MVA) is a promising viral vector platform for the development of an H5N1 influenza vaccine. Predinical assessment of MVA-based H5N1 vaccines showed their immunogenicity and safety in different animal models. We aimed to assess the safety and immunogenicity of the MVA-haemagglutinin-based H5N1 vaccine MVA-H5-sfMR in healthy individuals.

机译：背景改良的牛痘病毒安卡拉（MVA）是用于开发H5N1流感疫苗的有前途的病毒载体平台。对基于MVA的H5N1疫苗的常规评估表明，它们在不同动物模型中的免疫原性和安全性。我们旨在评估基于MVA-血凝素的H5N1疫苗MVA-H5-sfMR在健康个体中的安全性和免疫原性。

著录项

来源
《The Lancet infectious diseases》 |2014年第12期|共12页
作者
Kreijtz Joost H. C. M.; Goeijenbier Marco; Moesker Fleur M.; van den Dries Lennert; Goeijenbier Simone; De Gruyter Heidi L. M.; Lehmann Michael H.; de Mutsert Gerrie; van de Vijver David A. M. C.; Volz Asisa; Fouchier Ron A. M.; van Gorp Eric C. M.; Rimmelzwaan Guus F.; Sutter Gerd; Osterhaus Albert D. M. E.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类传染病;
关键词

相似文献

外文文献
中文文献
专利

1. Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial [J] . Kreijtz Joost H. C. M., Goeijenbier Marco, Moesker Fleur M., The Lancet infectious diseases . 2014,第12期

机译：改良的痘苗病毒-基于安卡拉的甲型H5N1流感疫苗的安全性和免疫原性：一项随机，双盲1 / 2a期临床试验
2. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: A Randomised, double-blind, placebo-controlled, phase 1 study [J] . GurwithM., LockM., TaylorE.M., The Lancet infectious diseases . 2013,第3期

机译：用于H5N1流感的口服复制型腺病毒4型血清复制载体疫苗的安全性和免疫原性：一项随机，双盲，安慰剂对照的1期研究
3. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China [J] . Wang Shi-Yuan, Liu Shu-Zhen, Chu Kai, Expert review of vaccines . 2017,第7a12期

机译：在参与者> / = 3岁以下的灭活四价流感疫苗候选与灭活三价流感疫苗的免疫原性和安全性：中国的双盲，随机，平行控股第三阶段临床试验
4. A double-blind, randomized phase II trial of thesafety and immunogenicity of 26-valent group A streptococcus vaccine in healthy adults [C] . Shelly A. McNeil, Scott A. Halperin, Joanne M. Langley, Lancefield International Symposium on Streptococci and Streptococcal Diseases . 2006

机译：一种双盲，随机期II试验，对健康成人的26岁的26岁群体的疫苗疫苗
5. Development of a broadly reactive vaccine for highly pathogenic H5N1 influenza [D] . Giles, Brendan Michael. 2011

机译：高致病性H5N1流感广泛反应疫苗的研制
6. Randomized double-blind multi-center phase III clinical trial to evaluate the immunogenicity and safety of MG1109 (egg-based pre-pandemic influenza A/H5N1 vaccine) in healthy adults [O] . Joon Young Song, Min Joo Choi, Ji Yun Noh, 2017

机译：随机双盲多中心III期临床试验评估健康成年人MG1109（基于鸡蛋的大流行性流感A / H5N1疫苗）的免疫原性和安全性
7. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study [O] . Gurwith Marc, Lock Michael, Taylor Eve M, 2013

机译：H5N1流感口服复制型腺病毒4型血清复制载体疫苗的安全性和免疫原性：一项随机，双盲，安慰剂对照的1期研究

Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: a randomised, double-blind phase 1/2a clinical trial

摘要

著录项

相似文献

相关主题

期刊订阅